GlycoMimetics To Present Interim Analysis Of Phase 1b Proof-Of-Concept Study At American Association For Cancer Research Apr. 10, 2021
GlycoMimetics To Present Interim Analysis Of Phase 1b Proof-Of-Concept Study At American Association For Cancer Research Apr. 10, 2021
GlycoMimetics, Inc. (NASDAQ:GLYC) today announces that an abstract presenting the interim analysis of a Phase 1b proof-of-concept study of GMI-1359, the Company’s dual antagonist of E-selectin and CXCR4, has been accepted for presentation at the American Association of Cancer Research (AACR) 2021 Annual Meeting, to be held virtually on April 10-15 and May 17-21. Preclinical studies indicate that targeting both E-selectin and CXCR4, a chemokine receptor, with a single compound could improve efficacy in the treatment of cancers that affect the bone and bone marrow, such as breast and prostate cancer. A second abstract also accepted for presentation highlights, for the first time, preclinical data in pancreatic cancer for the Company’s novel dual antagonist of galectin-3 and E-selectin, GMI-1757. The latter is featured as a late-breaking abstract on the compound’s impact on fibrosis, mononuclear cell infiltration, and anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model.
GlycoMimtics，Inc.(纳斯达克：甘露糖)今天宣布，一份介绍该公司E-选择素和CXCR4双重拮抗剂GMI-1359 1b期概念验证研究中期分析的摘要已被接受，将在4月10日至15日和5月17日至21日举行的美国癌症研究协会(AACR)2021年年会上提交。临床前研究表明，用一种化合物同时针对E-选择素和趋化因子受体CXCR4，可以提高治疗影响骨骼和骨髓的癌症的疗效，如乳腺癌和前列腺癌。第二份摘要也被接受为报告，第一次强调了该公司新的Galectin-3和E-选择素双重拮抗剂GMI-1757在胰腺癌的临床前数据。后者是关于该化合物在胰腺癌模型中对纤维化、单核细胞浸润和抗PD-L1治疗活性的影响的最新摘要。
GlycoMimetics Chief Executive Officer Rachel King said, “We look forward to sharing results from two programs in our advancing portfolio at the upcoming AACR meeting, including the interim analysis of Phase 1b clinical data supporting further advancement of the GMI-1359 program. We are extremely proud to be collaborating with the Duke Cancer Institute on this important work, which we believe holds great promise in delivering a novel approach to treating cancers with bone involvement.”
GlycoMimtics首席执行官雷切尔·金说：“我们期待着在即将到来的AACR会议上分享我们正在推进的产品组合中的两个项目的结果，包括对支持GMI-1359项目进一步推进的1b期临床数据的中期分析。我们非常自豪能与杜克癌症研究所在这项重要工作上进行合作，我们相信这项工作在提供一种治疗涉及骨骼的癌症的新方法方面大有希望。“
Details on GlycoMimetics e-presentations at the AACR Meeting are as follows:
GlycoMimtics在AACR会议上的电子演讲详情如下：
Title: “Development of GMI-1359, a Novel Agent Targeting Tumor-microenvironment Cross-talk in Bone Metastatic Breast Cancer”
Presenter: Dorothy Sipkins, M.D., Ph.D., Duke Cancer Institute
Session: e-Presentation
Date and Time: Saturday, April 10, 2021 (available online through Monday, June 21)
标题：骨转移性乳腺癌肿瘤-微环境交互作用新药GMI-1359的研制主讲人：多萝西·西普金斯(Dorothy Sipkins)，医学博士，杜克癌症研究所(Duke Cancer Institute)博士会话：电子演示文稿日期和时间：2021年4月10日(星期六)(网上发售至6月21日(星期一))
Title: A novel glycomimetic compound (GMI-1757) with dual functional antagonism to E-selectin and galectin-3 attenuates fibrosis, facilitates mononuclear cell infiltration and optimizes anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model
Presenter: William E. Fogler, M.D., GlycoMimetics
Session: e-Presentation
Date and Time: Saturday, April 10, 2021 (available online through Monday, June 21)
标题：一种对E-选择素和Galectin-3具有双重功能拮抗作用的拟糖化合物(GMI-1757)在胰腺癌模型中减轻纤维化，促进单个核细胞浸润，优化抗PD-L1治疗活性主讲人：威廉·E·福格勒(William E.Fogler)，医学博士，糖仿生学会话：电子演示文稿日期和时间：2021年4月10日(星期六)(网上发售至6月21日(星期一))
译文内容由第三方软件翻译。